Annual Net Income
-$17.19 M
+$7.08 M+29.18%
December 31, 2023
Summary
- As of February 8, 2025, BCLI annual net profit is -$17.19 million, with the most recent change of +$7.08 million (+29.18%) on December 31, 2023.
- During the last 3 years, BCLI annual net income has risen by +$14.62 million (+45.96%).
- BCLI annual net income is now -67056.25% below its all-time high of -$25.60 thousand, reached on March 31, 2002.
Performance
BCLI Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Net Income
-$2.71 M
-$167.00 K-6.57%
September 30, 2024
Summary
- As of February 8, 2025, BCLI quarterly net profit is -$2.71 million, with the most recent change of -$167.00 thousand (-6.57%) on September 30, 2024.
- Over the past year, BCLI quarterly net income has dropped by -$167.00 thousand (-6.57%).
- BCLI quarterly net income is now -1081.16% below its all-time high of $276.00 thousand, reached on December 31, 2017.
Performance
BCLI Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Net Income
-$14.23 M
-$1.48 M-11.63%
September 30, 2024
Summary
- As of February 8, 2025, BCLI TTM net profit is -$14.23 million, with the most recent change of -$1.48 million (-11.63%) on September 30, 2024.
- Over the past year, BCLI TTM net income has dropped by -$1.48 million (-11.63%).
- BCLI TTM net income is now -165341.86% below its all-time high of -$8600.00, reached on June 30, 2002.
Performance
BCLI TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Net Income Formula
Net Income = Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses
BCLI Net Income Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +29.2% | -6.6% | -11.6% |
| 3 y3 years | +46.0% | -6.6% | -11.6% |
| 5 y5 years | -23.3% | -6.6% | -11.6% |
BCLI Net Income Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +29.7% | -120.9% | +61.5% | -11.6% | +44.1% |
| 5 y | 5-year | at high | +46.0% | -120.9% | +77.1% | -11.6% | +55.3% |
| alltime | all time | <-9999.0% | +46.0% | -1081.2% | +83.7% | <-9999.0% | +55.3% |
Brainstorm Cell Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.71 M(+6.6%) | -$14.23 M(+11.6%) |
| Jun 2024 | - | -$2.54 M(-25.3%) | -$12.75 M(-17.9%) |
| Mar 2024 | - | -$3.40 M(-39.0%) | -$15.53 M(-9.6%) |
| Dec 2023 | -$17.19 M(-29.2%) | -$5.58 M(+355.0%) | -$17.19 M(+3.4%) |
| Sep 2023 | - | -$1.23 M(-77.0%) | -$16.63 M(-25.3%) |
| Jun 2023 | - | -$5.33 M(+5.3%) | -$22.26 M(-7.1%) |
| Mar 2023 | - | -$5.06 M(+0.8%) | -$23.98 M(-1.2%) |
| Dec 2022 | -$24.28 M(-0.7%) | -$5.02 M(-26.8%) | -$24.28 M(-4.6%) |
| Sep 2022 | - | -$6.86 M(-2.6%) | -$25.45 M(+6.4%) |
| Jun 2022 | - | -$7.04 M(+31.4%) | -$23.93 M(+3.3%) |
| Mar 2022 | - | -$5.36 M(-13.4%) | -$23.16 M(-5.3%) |
| Dec 2021 | -$24.46 M(-23.1%) | -$6.19 M(+16.0%) | -$24.46 M(-18.7%) |
| Sep 2021 | - | -$5.34 M(-14.9%) | -$30.08 M(+2.9%) |
| Jun 2021 | - | -$6.27 M(-5.9%) | -$29.23 M(-3.7%) |
| Mar 2021 | - | -$6.66 M(-43.6%) | -$30.36 M(-4.6%) |
| Dec 2020 | -$31.81 M(+36.8%) | -$11.81 M(+163.3%) | -$31.81 M(+14.9%) |
| Sep 2020 | - | -$4.49 M(-39.3%) | -$27.69 M(-4.0%) |
| Jun 2020 | - | -$7.39 M(-8.9%) | -$28.83 M(+9.5%) |
| Mar 2020 | - | -$8.11 M(+5.5%) | -$26.34 M(+13.3%) |
| Dec 2019 | -$23.25 M(+66.7%) | -$7.69 M(+36.5%) | -$23.25 M(+11.0%) |
| Sep 2019 | - | -$5.63 M(+15.0%) | -$20.94 M(+13.3%) |
| Jun 2019 | - | -$4.90 M(-2.5%) | -$18.49 M(+10.8%) |
| Mar 2019 | - | -$5.03 M(-6.6%) | -$16.68 M(+19.6%) |
| Dec 2018 | -$13.95 M(+181.7%) | -$5.38 M(+69.5%) | -$13.95 M(+68.3%) |
| Sep 2018 | - | -$3.18 M(+2.7%) | -$8.29 M(+10.3%) |
| Jun 2018 | - | -$3.09 M(+34.5%) | -$7.52 M(+37.5%) |
| Mar 2018 | - | -$2.30 M(-932.6%) | -$5.46 M(+10.4%) |
| Dec 2017 | -$4.95 M(-0.6%) | $276.00 K(-111.5%) | -$4.95 M(-15.4%) |
| Sep 2017 | - | -$2.40 M(+131.1%) | -$5.85 M(+15.8%) |
| Jun 2017 | - | -$1.04 M(-41.7%) | -$5.05 M(+1.6%) |
| Mar 2017 | - | -$1.78 M(+186.1%) | -$4.98 M(-0.1%) |
| Dec 2016 | -$4.98 M(-41.3%) | -$624.00 K(-61.1%) | -$4.98 M(-13.2%) |
| Sep 2016 | - | -$1.61 M(+66.9%) | -$5.74 M(-14.8%) |
| Jun 2016 | - | -$962.00 K(-46.3%) | -$6.74 M(-16.2%) |
| Mar 2016 | - | -$1.79 M(+29.3%) | -$8.04 M(-5.3%) |
| Dec 2015 | -$8.49 M(-8.2%) | -$1.38 M(-46.8%) | -$8.49 M(-13.7%) |
| Sep 2015 | - | -$2.60 M(+14.9%) | -$9.83 M(+1.9%) |
| Jun 2015 | - | -$2.27 M(+1.3%) | -$9.65 M(+3.0%) |
| Mar 2015 | - | -$2.24 M(-18.1%) | -$9.37 M(+1.4%) |
| Dec 2014 | -$9.25 M(+88.7%) | -$2.73 M(+12.8%) | -$9.25 M(+19.6%) |
| Sep 2014 | - | -$2.42 M(+22.0%) | -$7.73 M(+20.9%) |
| Jun 2014 | - | -$1.98 M(-6.0%) | -$6.39 M(+7.9%) |
| Mar 2014 | - | -$2.11 M(+73.5%) | -$5.93 M(+21.0%) |
| Dec 2013 | -$4.90 M | -$1.22 M(+12.5%) | -$4.90 M(+15.0%) |
| Sep 2013 | - | -$1.08 M(-28.7%) | -$4.26 M(-1.6%) |
| Jun 2013 | - | -$1.52 M(+40.3%) | -$4.33 M(+18.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$1.08 M(+86.9%) | -$3.64 M(+6.1%) |
| Dec 2012 | -$3.43 M(-12.5%) | -$579.00 K(-49.7%) | -$3.43 M(-19.7%) |
| Sep 2012 | - | -$1.15 M(+38.6%) | -$4.27 M(+11.9%) |
| Jun 2012 | - | -$830.00 K(-4.8%) | -$3.82 M(-6.5%) |
| Mar 2012 | - | -$872.00 K(-38.7%) | -$4.08 M(+4.3%) |
| Dec 2011 | -$3.92 M(+62.0%) | -$1.42 M(+104.9%) | -$3.92 M(+31.4%) |
| Sep 2011 | - | -$694.00 K(-36.7%) | -$2.98 M(-0.3%) |
| Jun 2011 | - | -$1.10 M(+55.6%) | -$2.99 M(+19.3%) |
| Mar 2011 | - | -$705.00 K(+45.1%) | -$2.51 M(+3.7%) |
| Dec 2010 | -$2.42 M(+35.8%) | -$486.00 K(-31.0%) | -$2.42 M(+18.8%) |
| Sep 2010 | - | -$704.00 K(+14.7%) | -$2.04 M(+4.2%) |
| Jun 2010 | - | -$614.00 K(-0.2%) | -$1.95 M(+3.8%) |
| Mar 2010 | - | -$615.00 K(+497.1%) | -$1.88 M(+5.7%) |
| Dec 2009 | -$1.78 M(-48.7%) | -$103.00 K(-83.4%) | -$1.78 M(-22.7%) |
| Sep 2009 | - | -$621.00 K(+14.4%) | -$2.30 M(-4.4%) |
| Jun 2009 | - | -$543.00 K(+5.6%) | -$2.41 M(-11.5%) |
| Mar 2009 | - | -$514.00 K(-17.9%) | -$2.72 M(-21.5%) |
| Dec 2008 | -$3.47 M(-44.4%) | -$626.00 K(-14.0%) | -$3.47 M(-26.9%) |
| Sep 2008 | - | -$728.00 K(-15.0%) | -$4.75 M(-13.4%) |
| Jun 2008 | - | -$856.00 K(-32.2%) | -$5.49 M(-5.1%) |
| Mar 2008 | - | -$1.26 M(-33.8%) | -$5.78 M(-7.4%) |
| Dec 2007 | -$6.24 M(+59.1%) | -$1.91 M(+30.4%) | -$6.24 M(+43.9%) |
| Sep 2007 | - | -$1.46 M(+26.9%) | -$4.34 M(+10.5%) |
| Jun 2007 | - | -$1.15 M(-33.2%) | -$3.92 M(+15.9%) |
| Mar 2007 | - | -$1.72 M(+64.5%) | -$3.39 M(+5.8%) |
| Dec 2006 | -$3.92 M(+18.3%) | - | - |
| Sep 2006 | - | -$1.05 M(+70.4%) | -$3.20 M(+0.3%) |
| Jun 2006 | - | -$614.90 K(0.0%) | -$3.19 M(-3.8%) |
| Mar 2006 | - | -$614.90 K(-33.4%) | -$3.32 M(-1.3%) |
| Mar 2006 | -$3.32 M(-82.4%) | - | - |
| Dec 2005 | - | -$923.90 K(-11.0%) | -$3.36 M(-82.4%) |
| Sep 2005 | - | -$1.04 M(+40.3%) | -$19.04 M(-2.7%) |
| Jun 2005 | - | -$739.80 K(+12.6%) | -$19.58 M(+3.8%) |
| Mar 2005 | -$18.84 M(>+9900.0%) | -$657.30 K(-96.0%) | -$18.86 M(+3.4%) |
| Dec 2004 | - | -$16.60 M(+954.2%) | -$18.23 M(+1007.6%) |
| Sep 2004 | - | -$1.57 M(+7435.9%) | -$1.65 M(+1900.4%) |
| Jun 2004 | - | -$20.90 K(-41.6%) | -$82.30 K(+12.3%) |
| Mar 2004 | -$73.30 K(+56.6%) | -$35.80 K(+145.2%) | -$73.30 K(+35.7%) |
| Dec 2003 | - | -$14.60 K(+32.7%) | -$54.00 K(+2.1%) |
| Sep 2003 | - | -$11.00 K(-7.6%) | -$52.90 K(+5.6%) |
| Jun 2003 | - | -$11.90 K(-27.9%) | -$50.10 K(+7.1%) |
| Mar 2003 | -$46.80 K(+82.8%) | -$16.50 K(+22.2%) | -$46.80 K(+54.5%) |
| Dec 2002 | - | -$13.50 K(+64.6%) | -$30.30 K(+80.4%) |
| Sep 2002 | - | -$8200.00(-4.7%) | -$16.80 K(+95.3%) |
| Jun 2002 | - | -$8600.00 | -$8600.00 |
| Mar 2002 | -$25.60 K | - | - |
FAQ
- What is Brainstorm Cell Therapeutics annual net profit?
- What is the all time high annual net income for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual net income year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly net income year-on-year change?
- What is Brainstorm Cell Therapeutics TTM net profit?
- What is the all time high TTM net income for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics TTM net income year-on-year change?
What is Brainstorm Cell Therapeutics annual net profit?
The current annual net income of BCLI is -$17.19 M
What is the all time high annual net income for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual net profit is -$25.60 K
What is Brainstorm Cell Therapeutics annual net income year-on-year change?
Over the past year, BCLI annual net profit has changed by +$7.08 M (+29.18%)
What is Brainstorm Cell Therapeutics quarterly net profit?
The current quarterly net income of BCLI is -$2.71 M
What is the all time high quarterly net income for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly net profit is $276.00 K
What is Brainstorm Cell Therapeutics quarterly net income year-on-year change?
Over the past year, BCLI quarterly net profit has changed by -$167.00 K (-6.57%)
What is Brainstorm Cell Therapeutics TTM net profit?
The current TTM net income of BCLI is -$14.23 M
What is the all time high TTM net income for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high TTM net profit is -$8600.00
What is Brainstorm Cell Therapeutics TTM net income year-on-year change?
Over the past year, BCLI TTM net profit has changed by -$1.48 M (-11.63%)